Research programme: tropomyosin receptor kinase degraders - Cullgen
Latest Information Update: 03 Sep 2024
Price :
$50 *
At a glance
- Originator Cullgen
- Class Analgesics; Small molecules
- Mechanism of Action Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute pain; Pain
Most Recent Events
- 07 Aug 2024 Preclinical trials in Acute pain in USA (unspecified route) prior to August 2024 (Cullgen pipeline, August 2024)
- 07 Aug 2024 Preclinical trials in Pain in USA (unspecified route) prior to August 2024 (Cullgen pipeline, August 2024)